Lactobacillus plantarum KSFY06 and geniposide counteract montmorillonite‐induced constipation in Kunming mice

Yi Gan, Jie Liang, Wenjing Diao, Xianrong Zhou, Jianfei Mu, Liang Pang, Fang Tan, Xin ZhaoFood 2020 · DOI

TL;DR

This study demonstrates that a combination of the probiotic Lactobacillus plantarum KSFY06 (LP-KSFY06) and geniposide, a natural compound, effectively alleviates constipation induced by montmorillonite in mice. The synergistic effect of this combination not only improved fecal parameters and gut motility biomarkers but also modulated key gene expressions related to intestinal health, suggesting a promising therapeutic strategy for constipation.

What Problem Does This Paper Address?

Constipation is a widespread gastrointestinal disorder affecting millions globally, often leading to discomfort and a reduced quality of life. While various treatments exist, including laxatives and prokinetic agents, long-term use can lead to dependence and side effects. Furthermore, the exact pathogenesis of constipation remains complex, involving factors like gut microbiota dysbiosis, impaired intestinal motility, and altered neurotransmitter signaling. This paper addresses the need for effective and safe therapeutic solutions by investigating the potential synergistic effects of a probiotic (L. plantarum KSFY06) and a natural compound (geniposide) in counteracting constipation, aiming to provide a more holistic approach to managing this condition.

Methods

The researchers employed a multi-faceted approach to evaluate the efficacy of LP-KSFY06 and geniposide in a mouse model of constipation.

  • Constipation Model: Montmorillonite powder was administered to Kunming mice to induce constipation, mimicking key pathological features.
  • Treatment Groups: Mice were divided into five groups: normal control, model (constipated), LP-KSFY06 treatment, geniposide treatment, and a combined LP-KSFY06 + geniposide (LP+G) treatment.
  • Fecal Parameter Analysis: Stool weight and moisture content were measured to assess the direct impact on defecation.
  • Gastrointestinal Transit: Activated carbon was used to track the speed of food passage through the digestive system, and the time to the first black stool was recorded as an indicator of defecation ease.
  • Histological Examination: Hematoxylin and eosin (H&E) staining was used to examine the morphology of small intestinal villi, looking for signs of damage and repair.
  • Biomarker Analysis: Serum levels of key gastrointestinal motility-related biomarkers, including motilin (MTL), acetylcholinesterase (AChE), substance P (SP), vasoactive intestinal peptide (VIP), endothelin-1 (ET-1), and somatostatin (SS), were quantified using ELISA kits.
  • Gene Expression Analysis: Quantitative PCR (qPCR) was performed on small intestine tissue to measure the mRNA expression levels of genes involved in intestinal motility and health, such as c-Kit, SCF, GDNF, iNOS, TRPV1, and COX-2.
  • Statistical Analysis: Standard statistical methods, including one-way ANOVA and Duncan's multiple range test, were used to determine significant differences between groups.

Datasets

Not discussed in the paper. The study utilized a mouse model and collected data from these animals.

Key Insights and Ideas

  • Synergistic Action: The most significant finding is the synergistic effect of combining L. plantarum KSFY06 with geniposide. While both agents showed some benefit individually, their combination yielded superior results in alleviating constipation. This highlights the potential for multi-component therapies in treating complex conditions.
  • Beyond Symptom Relief: The study goes beyond simply measuring stool output. It delves into the underlying physiological mechanisms by examining neurotransmitter levels and gene expression, providing a more comprehensive understanding of how the treatment works.
  • Probiotic as an Enhancer: L. plantarum KSFY06 appears to act not just as an independent therapeutic but also as an enhancer for geniposide's efficacy. This suggests that probiotics can play a crucial role in optimizing the action of other therapeutic agents.
  • Gut Health Restoration: The observed repair of intestinal villi morphology in the combined treatment group, returning to near-normal levels, indicates a restorative effect on the gut lining, which is critical for overall digestive health.

Key Results

  • Improved Fecal Parameters: The LP+G combination significantly increased stool weight and moisture content compared to the model group, indicating improved defecation.
  • Reduced Defecation Time: The time to the first black stool was dramatically reduced from 182 minutes in the model group to 87 minutes in the LP+G group, signifying a substantial alleviation of defecation difficulty.
  • Maintained Body Weight: The LP+G treatment helped maintain body weight in constipated mice, which was significantly decreased in the untreated model group.
  • Biomarker Modulation: The LP+G group showed serum levels of gastrointestinal motility-related biomarkers that were closer to those of the normal group, with significant increases in excitatory peptides (MTL, VIP, gastrin, AchE, SP) and decreases in inhibitory peptides (ET-1, SS).
  • Gene Expression Regulation: The LP+G treatment significantly upregulated the expression of genes associated with intestinal motility and nerve cell development (c-Kit, SCF, GDNF) and downregulated genes linked to inflammation and reduced motility (iNOS, TRPV1, COX-2). The efficacy of LP+G was superior to that of sole treatments.

Limitations and Future Work

  • Mouse Model: While the mouse model provides valuable insights, it is an animal model, and direct translation to human efficacy requires further clinical trials.
  • Mechanism of Action: While the study identifies key biomarkers and gene expressions affected, the precise molecular mechanisms by which LP-KSFY06 enhances geniposide's action require deeper investigation.
  • Dosage Optimization: The study used specific dosages for LP-KSFY06 and geniposide. Further research could explore dose-response relationships to identify optimal therapeutic levels.
  • Clinical Trials: The authors explicitly state that clinical trials are necessary to verify the effectiveness of this combination in humans.
  • Long-term Effects: The study focused on a relatively short treatment period. Long-term studies would be beneficial to assess sustained efficacy and safety.

Summary updated

Abstract

Constipation is a common clinical manifestation of digestive system disorders and occurs worldwide. This study investigated the ability of <i>Lactobacillus plantarum</i> KSFY06 (LP-KSFY06) to promote the action of geniposide in preventing montmorillonite-induced constipation in Kunming mice, with the aim of providing a successful solution. The effects of LP-KSFY06 and geniposide on constipation were measured, and the results showed that the protective effect of geniposide on constipation was enhanced by LP-KSFY06 and that the combination resulted in increased weight, moisture content, and particle number of feces. The first black stool defecation time was decreased from 182 min to 87 min, which clearly indicates that defecating difficulty was alleviated in constipated mice. The synergic intervention of LP-KSFY06 and geniposide (LP + G) assisted in maintaining the body weight of constipated mice. The LP + G intervention significantly increased serum levels of motilin (MTL, 167.8 pg/ml), acetylcholinesterase (AChE, 45.3 pg/ml), substance P (SP, 61.0 pg/ml), vasoactive intestinal peptide (VIP, 70.5 pg/ml), endothelin-1 (ET-1, 16.1 pg/ml), and gastrin (73.0 pg/ml) and remarkably decreased somatostatin (SS, 35.2 pg/ml) when compared to those indexes in the LP-KSFY06 group and geniposide group. The LP + G treatment also significantly increased the mRNA expression of cluster of differentiation 117 (c-Kit), stem cell factor (SCF), glial cell-derived neurotrophic factor (GDNF), and remarkably downregulated the expression of inducible nitric oxide synthase (iNOS), transient receptor potential vanilloid-1 (TRPV1), and cyclooxygenase-2 (COX-2). The experimental results showed that the combination treatment has the strongest prevention effect against constipation, and LP-KSFY06 promotes the ability of geniposide to prevent constipation. Therefore, LP-KSFY06 is a potential probiotic strain with the capacity to prevent montmorillonite-induced constipation.
BibTeX
@inproceedings{gan2020i,
  author = {Yi Gan and Jie Liang and Wenjing Diao and Xianrong Zhou and Jianfei Mu and Liang Pang and Fang Tan and Xin Zhao},
  title = {{<i>Lactobacillus plantarum</i> KSFY06 and geniposide counteract montmorillonite‐induced constipation in Kunming mice}},
  booktitle = {Food},
  year = {2020},
  doi = {10.1002/fsn3.1814},
}
Figure